Astrazeneca Pharma India Limited - Company Profile

It is a pharma public limited company based in Bangalore, Karnataka, India, established in 1979.
1979 Bangalore, Karnataka, India Active
Last Updated:
About Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited, a active public limited company, was established on 11 July 1979 in Bangalore, Karnataka, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24231KA1979PLC003563. Registered under ROC Roc Bangalore. it is listed on BSE: 506820 and NSE: ASTRAZEN. It has an authorized capital of ₹5.00 Cr and a paid-up capital of ₹5.00 Cr.

Formerly known as Astra Idl Limited. It upholds a compliant status. In 2023, it reported revenue of ₹1,029.07 Cr and a net worth of ₹588.69 Cr. Employing 935 professional, Its leadership includes Revathy Ashok (Director), Hooi Bien Chuah (Director), Bhavana Agrawal (Cfo). Past directors included Sanjeev Kumar Panchal, Nurani Ramachandran Srinivasan, Rajesh Marwaha. It holds no open charges and ₹62.50 Cr settled loans. Its latest AGM occurred on 14 August 2025, with the balance sheet filed on 31 March 2025. It is based at Block N1, 12Th Floor,Manyata Embassy Business Park Rachenahalli, Outer Ring Road, Bangalore, Karnataka, 560045.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L24231KA1979PLC003563

  • Registration Number

    003563

  • Incorporation Date

    11 July 1979

  • Authorized Capital

    ₹5.00 Cr

  • Paid-Up Capital

    ₹5.00 Cr

  • ROC Code

    Roc Bangalore

  • Listing Status

    Listed (BSE: 506820, NSE: ASTRAZEN)

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 5.00 Cr
  • Paid Up Capital ₹ 5.00 Cr
  • Company Age 46 Year, 7 Months
  • Last Filing with ROC 31 Mar 2025
  • Satisfied Charges ₹ 62.50 Cr
  • Revenue Growth **** 25.44%
  • Profit Growth **** 61.19%
  • Ebitda **** 91.60%
  • Net Worth 15.12%
  • Total Assets **** 14.98%
Company report

Astrazeneca Pharma India Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Astrazeneca Pharma India Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report Banner Element
Who are the key members and board of directors at Astrazeneca Pharma India Limited?
Current Directors
Name Designation Appointment Date Status
Revathy Ashok Director 02 Dec 2016 Current
Hooi Bien Chuah Director 09 Nov 2023 Current
Bhavana Agrawal Cfo 01 Oct 2023 Current
Sylvia Lorena Varela Ramon Director 21 Dec 2023 Current
Jesus Javier Diaz Ropero Esteso Director 13 Nov 2024 Current
Monica Widhani Director 25 Sep 2024 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 01 Jan 2023 Past
Pramod Abcsdd Company Secretary 31 Jul 2011 Past
Pramod Abcsdd Additional Director 13 Sep 2017 Past
Pramod Abcsdd Director 06 Feb 2019 Past
Pramod Abcsdd Director 02 Dec 2016 Past
Pramod Abcsdd Director - Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Astrazeneca Pharma India.

Astrazeneca Pharma India Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.44% increase. The company also saw a substantial improvement in profitability, with a 61.19% increase in profit. The company's net worth Soared by an impressive increase of 15.12%.

Astrazeneca Pharma India revenue growth over time
Astrazeneca Pharma India profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
25.44%
*******
*******
*******
*******
Revenue from Operations
*******
24.50%
*******
*******
*******
*******
Total Assets
*******
14.98%
*******
*******
*******
*******
Profit or Loss
*******
61.19%
*******
*******
*******
*******
Net Worth
*******
15.12%
*******
*******
*******
*******
EBITDA
*******
91.60%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Astrazeneca Pharma India?

In 2023, Astrazeneca Pharma India had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹0

Satisfied Charges

₹625,000,000.00

Charges Breakdown by Lending Institutions
  • Il & Fs Trust Company Limited : 62.50 Cr
Latest Charge Details
Date Lender Amount Status
16 Jan 2008 Il & Fs Trust Company Limited ₹62.50 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Astrazeneca Pharma India?

Astrazeneca Pharma India has a workforce of 935 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Astrazeneca Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astrazeneca Pharma India's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Astrazeneca Pharma India
Recent Activity within the Organization
  • Annual General Meeting

    Astrazeneca Pharma India Limited last Annual general meeting of members was held on 14 Aug 2025 as per latest MCA records. was recorded as a recent event.

  • Director Appointment

    Praveen Rao Akkinepally was appointed as a Managing Director was appointed as a Managing Director on 01 Jul 2025 & has been associated with this company since 7 months 11 days . was recorded as a recent event.

  • Balance Sheet

    Astrazeneca Pharma India Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore. was recorded as a recent event.

  • Director Appointment

    Progress on Jesus Javier Diaz Ropero Esteso was appointed as a Director was appointed as a Director on 13 Nov 2024 & has been associated with this company since 1 year 2 months . was documented.

  • Director Appointment

    The activity Monica Widhani was appointed as a Director was appointed as a Director on 25 Sep 2024 & has been associated with this company since 1 year 4 months . was completed.

  • Director Appointment

    The activity Bhavana Agrawal was appointed as a CFO was appointed as a CFO on 15 Mar 2024 & has been associated with this company since 1 year 10 months . was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Astrazeneca Pharma India Limited?

The CIN of Astrazeneca Pharma India Limited is L24231KA1979PLC003563.

Where is Astrazeneca Pharma India Limited headquartered?

Astrazeneca Pharma India Limited is headquartered at Block N1, 12Th Floor,Manyata Embassy Business Park Rachenahalli, Outer Ring Road, Bangalore, Karnataka, 560045.

When was Astrazeneca Pharma India Limited incorporated?

Astrazeneca Pharma India Limited was incorporated on 11 July 1979.

Who are the current directors of Astrazeneca Pharma India Limited?
What is the primary industry of Astrazeneca Pharma India Limited?

The primary industry of Astrazeneca Pharma India Limited is Manufacturing.

Is Astrazeneca Pharma India Limited a listed company?

Astrazeneca Pharma India Limited is listed. It is listed on BSE: 506820 and NSE: ASTRAZEN.

What is the capital structure of Astrazeneca Pharma India Limited?

The authorized capital of Astrazeneca Pharma India Limited is ₹5.00 Cr, and the paid-up capital is ₹5.00 Cr.

What is the compliance status of Astrazeneca Pharma India Limited?

The compliance status of Astrazeneca Pharma India Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available